Executive Summary

Janssen pharmaceutical is a pharmaceutical company which is located in Belgium and its headquarters is in Beerse, Antwerp, Belgium. Janssen provides medicines in many areas in the health sector and several therapeutic areas.

The company also focuses on conducting great and deeper research in many different areas including neurological disorders, mental illness, oncology, allergies, fungal infections and gastrointestinal disorders.

In its development, manufacturing and distribution of its products, Janssen has had issues with various organizations, people and also the state over its products’ liabilities and has faced many lawsuits of which some have been settled and some have not been settled yet. 

-New Jersey Lawsuit about Opioids;

The state of New Jersey filed a lawsuit against Janssen Pharmaceuticals Company in November 2018. The state accused the company of minimizing or hiding the risks posed by opioid addiction when it was marketing the opioids targeting older people and other patients who had very little knowledge of opioids. This accusation led to this litigation and still the lawsuit is still on where no settlement has actually been reach or any compensation.

History of Janssen Pharmaceuticals

Janssen Pharmaceutical was established in 1953 by a Belgium researcher called Dr. Paul Janssen. He then established a research laboratory called Janssen pharmaceutica where he started doing his research for many therapies and medicines.

Dr. Janssen’s research laid quite a great foundation for over 80 medicines currently manufactured and developed by the company in saving many lives in the world today.

In 1961, Janssen pharmaceuticals joined Johnson & Johnson Company which is a pharmaceutical company as a subsidiary. It continued to search for solutions to change peoples’ lives.

In 1988, Janssen pharmaceuticals in Australia joined with Cilag, also another research company in chemical biotechnology. These two companies have highly joined forces and have spread widely all over the world and now they are called Janssen.

Subsidiaries of Janssen Pharmaceuticals

1. XO1 Limited

Janssen pharmaceuticals acquired Xo1 limited in March 2015. Xo1 limited is a privately owned biopharmaceutical company which was founded in order to help in developing the anti-thrombin antibody ichorcumab.

Ichorcumab is the human antibody which is developed to mimic the activities of the human antibody which produces ant coagulated state without necessary predispositioning to bleeding.

1. Corimmun

It is a drug development company that majorly focuses on therapeutics and heart diagnostics and vascular diseases. The company is located in Bayern Germany.

Janssen acquired Corimmun Company in July 2012. The company will help a lot in the areas of the heart and other vascular disorders or problems.

This acquisition shows that Janssen pharmaceuticals are highly committed to invest highly in the area of science specifically in the areas of great or urgent medical need. This ensures that new therapies are designed to improve the patience needs and also the lives of people all over the world.

Popular Products of Janssen Pharmaceuticals

1. Risperdal

Its generic name is called Risperidone. It is an antipsychotic medicine which mainly works by changing the chemicals in the human brain. It is mainly used to treat schizophrenia in both adults and children but children who are over 13 years old. 

This medicine is also used to treat the bipolar disorder symptoms in adults and children above 10 years old.

The medicine has some side effects and when you encounter them then consult the doctor e.g. difficulty breathing, swelling of your tongue, face and throat.

1. Nizoral Topical

Its generic name is called ketoconazole topical. It meant for the skin and it is antifungal drug used to treat infections such as dandruff, ringworm and athlete’s foot.

It is also used to treat pityriasis which is a fungal infection causing scaly discolored skin patches mostly on the chest, neck, legs or arms.

It should be used exactly as the prescription of the doctor and always wash your hands before and after using this medicine.

Its side effects mostly include thinning hair, shortness of breath, mild itching.

1. Prezcobix

Its generic name is called Cobicistat and darunavir. It contains a combination of darunavir and cobicistat where Darunavir is an antiviral medicine which prevents human immunodeficiency virus (HIV) from getting multiplied in the human body. Cobicistat on the other hand reduces the action of the enzymes in the liver that are used to break down some antiviral medicines.

With other medicines, it works well to treat HIV in adults, the virus that causes AIDS. It is not a cure for AIDS.

It should be used exactly as it was described by the doctor and should always be taken with food. Ensure frequent medical tests when using this medicine.

1. Elmiron

This is another product of Janssen pharmaceuticals. Its generic name is called pentosan polysulfate sodium. This medicine works like a blood thinner that is used to prevent blood clotting. It is also used to treat bladder pain and discomfort.

This medicine should be taken on an empty stomach at least 1 hour before any meal or 2 hours after having a meal.

Use this medicine as recommended by the doctor and do not use it for longer or shorter as prescribed by the doctor. Always check for certain effects when using this drug.

1. Axert

Its generic name is also called Almotriptan. This is used for the treatment of headache. It narrows the blood vessels around the brain and reduces certain substances in the body that can always trigger headache pain and nausea.

It is used to treat headaches which are migraine in adults and children or adolescents who are 12 years old. It always treats headache that has always began and cannot prevent any headache from occurring or happening.

1. Darzalex

The generic name for this product is called Daratumumab. It is a monoclonal antibody that is being used to block certain protein in the body that affects tumor cell growth. These antibodies are produced and only to target and destroy certain cells in the body.

It is also used to treat bone marrow cancer where it is usually given after all other treatments having failed totally to function.

Its common side effects includes; shortness of breath, fever, swelling in your hands or feet, trouble getting a sleep.

This medicine is given as an infusion into the vein. You will need frequent medical tests and it can affect the blood typing tests up to at least 6 months after stopping to take this medication.

1. Xarelto

It generic name is Rivaroxaban. This medicine is used to treat a blood clotting type called Deep Vein Thrombosis (DVT) which can easily lead to blood clotting in the lungs.

It is used in people with a heart rhythm disorder so that it can lower the risk of stroke which the blood clotting can cause. It is also given together with aspirin to lower the risk of serious heart problems, stroke and heart attack.

You should not use this medicine if you have; a bleeding disorder, uncontrolled high blood pressure, stomach or intestinal bleeding or ulcers and hemorrhagic stroke.

Take this medicine as prescribed by the doctor and do not over or under dose.

Product Recalls of Janssen Pharmaceuticals

1. 2018 Ortho – Novum Recall

Janssen pharmaceuticals issued a voluntary recall of Ortho – Novum in November 2018. This recall was due to incorrect veridate instructions. This recall was up to the pharmacy level. The patient information which was provided inside did not at all include the appropriate of the required information or instructions for the veridate dispenser.

The major risk that was involved in taking Ortho – Novum without using the clear guidelines and instructions for the correct use is that the affected patient could take the pills in the manner in which is not correct which could result in breakthrough bleeding and pregnancy which is not intended.

The Ortho – Novum pills are mainly used in the prevention of pregnancy for those who prefer to use these pills as the method of preventing pregnancy or as contraceptive.

The Ortho – Novum itself was very safe with the right instructions inside. This recall only affected the distribution in the US. No lawsuit has been filed concerning this recall yet and no adverse reactions have been reported so far.

1. 2013 Risperdal Consta Recall

Janssen pharmaceuticals made a recall in September 2013 for Risperdal Consta, a product they manufacture. This recall was aimed at wholesalers, distributors, health providers and pharmacies.

This medicine is an anti-psychotic medication which is mainly used to treat bipolar disorder and schizophrenia. Unlike the Risperdal basic pill, it is injected.

This recall was made after discovering a mold during the routine checking and testing processes. This prompted the company to make this recall. 

Since this recall, there has not been any complain or lawsuit filed concerning this recall and the reactions thereafter of any effects of this mold.

Janssen Pharmaceuticals Settlements

1. Xarelto Litigation settlement

In March 2019, Janssen pharmaceuticals together with Bayer pharmaceuticals settled $775 million over Xarelto claims and lawsuits. This case came about after patients who were affected sued the drug makers over failure to warn patients of the danger the drug would cause of bleeding episodes.

This settlement put to an end over 25,000 lawsuits by the state and the federal claims that surrounded this issue.

1. Montana $5.9 Settlement

In March 2014, Janssen agreed to pay and settle a claim that was filed by Montana physicians for an amount of $5.9 million.

In this case, the company was accused of employing illegal and deceptive means in the marketing of antipsychotic drug Risperdal. The suit alleged that Janssen highly deceived consumers and Montana that the product is very safe and quite effective for various conditions.

The company agreed to settle the case for $5.9 million but did not admit any liability or wrongdoing.

Sources:

https://www.crunchbase.com/organization/janssen-pharmaceuticalshttps://www.janssen.com/australia/about-us/our-historyhttps://www.fda.gov/Safety/Recalls/ucm625012.html

https://www.drugs.com/manufacturer/janssen-pharmaceuticals-inc-74.html

Executive Summary

Mitsubishi Tanabe Pharma Corporation is a Japanese pharmaceuticals company, a subsidiary of Mitsubishi Chemical Holdings Corporation. It is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The medical supplies business is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Company’s subsidiaries receive raw materials from the company and sell products locally.

History of Mitsubishi Tanabe Pharma

Takeda Kasei Co., Ltd. was established in 1940 by Chobei Takeda & Co., Ltd. (present-day Takeda Pharmaceutical Company) and Nippon Kasei Chemical Co. Ltd. (present-day Mitsubishi Chemical Corporation) and built its first plant in Higashi-Yoshitomi-mura, Fukuoka Prefecture. The company changed its name in 1952 to Yoshitomi Pharmaceutical Co., Ltd. in 1946 and listed on Tokyo and Osaka stock exchanges in 1949.

The Blood Plasma Corporation of Japan was established in 1950 with head office and plant in Osaka. This company changed its name to Green Cross Corporation in 1964.

Green Cross Corporation was acquired by Yoshitomi Pharmaceutical in 1998, changing its name to Welfide Corporation in 2000. The founders of Green Cross Corporation included war criminals such as Kitano Masaji who performed torture and experimentations on humans in the Japanese military’s notorious Unit 731 during World War II. These crimes were recognized by the UN as extreme “crimes against humanity”.

In 1901 Motosaburo Tanabe established a pharmacy in Tokyo, which was incorporated in 1921 as Motosaburo Tanabe Shoten, changing its name in 1943 to Tokyo Tanabe Pharmaceuticals Co., Ltd.

Nippon Tar Industries was established in 1921, becoming Mitsubishi Chemical Industries, Ltd. in 1952. This company established a business alliance with Tokyo Tanabe Pharmaceuticals Co. in 1981, and changed its name to Mitsubishi Chemical Corporation following the 1984 merger with Mitsubishi Petrochemical Co., Ltd.

Mitsubishi Chemical Corporation and Tokyo Tanabe Pharmaceuticals Co. merged formally in 1999 and formed Mitsubishi-Tokyo Pharmaceuticals, Inc., to take over the combined pharmaceutical operations of the two companies.

Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation merged in 2001 to establish Mitsubishi Pharma Corporation, and this company joined again with Mitsubishi Chemical Corporation to create Mitsubishi Chemical Holdings Corporation in October 2005. In 2007, Mitsubishi Tanabe Pharma was born out of the merger between Tanabe Seiyaku and Mitsubishi Pharma.

In August 2014 the company announced it had agreed to collaborate with AstraZeneca to leverage the pair’s strengths, expertise and assets on diabetic nephropathy, in a bid to develop high quality drugs much quicker than working alone. According to the National Institute of Health, 60% to 70% of diabetic sufferers in the U.S. alone suffered from nerve disorders related to diabetic nephropathy. The three-year research agreement has the objective of creating new treatments to replace expensive and limited options currently in place, mainly being dialysis or kidney transplantation.

In July, 2017, the company acquired Neuroderm for $1.1 billion.

Subsidiaries of Mitsubishi Tanabe Pharma:

Among Mitsubishi Tanabe Pharma’s notable subsidiaries are:

• Yoshitomiyakuhin Corporation – Japan
• Mitsubishi Tanabe Pharma Factory Ltd. – Japan
• Tanabe Seiyaku Yoshiki Factory Co., Ltd. – Japan
• Mitsubishi Tanabe Pharma Holdings America, Inc. – USA 
• MP Healthcare Venture Management Inc. – USA
• Medicago Inc. – Canada
• Tianjin Tanabe Seiyaku Co., Ltd. – Asia
• NeuroDerm Ltd. – Europe

A full list of subsidiaries may be found here: https://www.mt-pharma.co.jp/e/ir/annual/pdf/CR_2018_en.pdf

Popular Pharmaceutical Products of Mitsubishi Tanabe Pharma

The top products of Mitsubishi Tanabe Pharma

1. Remicade – Treatment of rheumatoid arthritis (RA), Crohn’s disease, psoriasis, ulcerative colitis, Behcet’s disease with refractory uveoretinitis, and ankylosing spondylitis
2. Talion – Treatment of allergic disorders 
3. Maintate – Treatment of hypertension, angina pectoris, extrasystole, chronic heart failure, and atrial fibrillation
4. Kremezin – Treatment of chronic kidney disease
5. Tetrabik – Combined vaccine for diphtheria, pertussis, tetanus, and polio
6. Varicella vaccine – Freeze dried live attenuated varicella vaccine 

Product Recalls and Lawsuits

1. In 2011, Mitsubish Tanabe Corp recalled two million of its injectable medicines made at a facility in Ashikaga, Japan, because it cannot guarantee their quality. The products that were affected were 5mcg and 10mcg formulations of the arteriosclerosis treatment Liple (alprostadil); 2.5mg doses of corticosteroid Limethason Intravenous Injection (dexamethasone palmitate) used to treat rheumatoid arthritis; and 300mg and 500mg doses of the quinolone antibiotic Pazucross Injection (pazufloxacin mesylate).

Litigation Settlements

As of 2019, Mitsubishi Tanabe has not been involved in any remarkable litigation settlements. 

Sources:

https://www.mt-pharma.co.jp/e/ir/annual/pdf/CR_2018_en.pdf

https://www.mt-pharma.co.jp/shared/show.php?url=/e/ir/annual/index.html

https://en.wikipedia.org/wiki/Mitsubishi_Tanabe_Pharma

http://www.pharmafile.com/news/280111/mitsubishi-tanabe-recalls-two-million-injectables

https://www.mt-pharma.co.jp/shared/show.php?url=/e/ir/annual/index.html

Executive summary

Allergan is a global pharmaceutical company which is located in Dublin Ireland and also its headquarters are located there. It is mainly focused on developing, manufacturing and distributing pharmaceutical, regenerative medicine products, surgical, biological products plus healthcare devices.

The markets quite a range of its own products and leading brands in many areas which includes; urology, women’s health, medical aesthetics and dermatology, gastroenterology, eye care and the central nervous system.

The company is an open science leader which has helped it so much in developing game changing ideas and innovations for the better and great care of the patients. It has over 100 operations globally and dedicated in working with healthcare providers and physicians in delivering meaningful and very innovative treatments to support and help people around the world to have healthier and longer lives.

Allergan pharmaceuticals in its operation, has received a share of litigations and lawsuits concerning its products. A lawsuit currently in place includes;

• Los Angeles lawsuit against Seri Scaffold surgical mesh

In November 2016, a Los Angeles woman sued the company over its conspiracy with a doctor to promote the use of Seri Scaffold surgical mesh and Natrelle breast tissue in an experimental manner without her knowledge and consent. She sued the company for fraud, negligence and failure to warn her of the consequences and that Seri Scaffold surgical mesh did not receive clearance from FDA for use in breast cancer reconstruction. She is seeking punitive damages for the case. 

History of Allergan pharmaceuticals

Allergan was established in 1948 by Gavin S. Herbert a pharmacist and Dr. Parmis Khatibi. They created the first drug which was an allergy nose drop in Los Angeles and was marketed using the name Allergan. This eye drops then propelled the company to the eye care field from then henceforth.

The Allergan pharmaceuticals became a company in 1950 officially and it focused more on the eye care and eye care products by then being under private and became public in the year 1970. 

In 1980, the company merged with Smithkline Beckman which lasted for 9 years and in 1989, the two companies separated and which afterward was acquired by Smithkline Beecham.

Allergan has been involved in making major treatments falling under the umbrella of eye care, neuroscience and medical aesthetics. It has been involved in major acquisitions and expanding its base in the pharmaceutical industry globally.

Subsidiaries of Allergan pharmaceuticals

1. Zeltiq Aesthetics

In March 2017, Allergan pharmaceuticals acquired Zeltiq aesthetics at a cost of $2.5 billion for complete acquire becoming part of Allergan family.

Zeltiq Aesthetics is a company which was established in 2005 and is located in California United States.

It is a science based company which deals with medical devices in developing the non-evasive procedures focusing mostly on reducing the unwanted body fat tissues.

1. Envy Medical Inc.

This is the latest acquire of Allergan. It was acquired in March 2019 at an undisclosed fee. This company was established in 2002. It is a biotechnology company which provides dermatology plus medical aesthetics solutions.

The company is mostly involved in skin therapy which delivers in excellent skin health and appearance to address the issues of skin concerns. It has well perfected this area of skin therapy through Dermalinfusion which is the skin resurfacing treatment.

1. Bonti

Allergan acquired Bonti in September at a cost of $195 million. The company was established in 2015. It was formerly called Endurance Biotech and changed this name to Bonti in 2015. It is a biotechnology company based in California United States.

1. Elastagen

Elastagen is a company based in Sydney, New south Wales, Australia and was established in the year 2003. It was acquired by Allergan pharmaceuticals in February 2018 at a cost of $95 million.

This company focuses on treatment of the skin and offers solution to the skin care health. It is a medical company with products based on the human protein tropoelastin. Its technology platform has potentials in focusing many areas which includes; scar remodeling, skin rejuvenation and repair of tissues.

1. Tobira Therapeutics

Tobira therapeutics is a company which is mostly engaged in the research and developing of compounds used for treating life threatening and very infectious diseases or ailments. It is located in New Jersey, United States. The company was established in 2006.

In September 2016, Tobira therapeutics was acquired by Allergan pharmaceuticals at a cost of $1.7 billion. This made the company to become whole subsidiary of Allergan.

The life threatening diseases which this company is involved are like HIV/AIDS, hepatitis and other infectious conditions.

1. Chase pharmaceuticals

Chase pharmaceutical is a company which is focused in medical clinical developments of improved treatments for the central nervous system. It is located in Washington, United States. It was established in the year 2007.

It was acquired by Allergan pharmaceuticals in November 2016 at a cost of $125 million.

1. Motus Therapeutics

Motus therapeutics is a company which is involved in the treatment of metabolic diseases. It is located in Boston, Massachusetts, United States and was established in 2008.

The company was acquired by Allergan pharmaceuticals in October 2016 at a cost of $200 million making it a whole subsidiary of Allergan pharmaceuticals.

1. Forest Laboratories Holdings

In November 2014, Allergan pharmaceuticals acquired Forest Laboratories at accost of $66 billion. The company was established in 1992 and is based in Dublin Ireland.

This company focuses on developing, discovering and researching the therapeutics and pharmaceutical drugs for the unmet needs of patients all over the world.

Popular products of Allergan pharmaceuticals

1. Celexa

Its generic name is Citalopram. 

It belongs to the class of antidepressant agents which is widely used in the treatment of depression symptoms. It is always used in the treatment of depression as indicated in the label and is not also limited to the treatment of post stroke behaviors, ethanol abuse and sexual dysfunction and in children used for OCD (Obsessive compulsive disorder).

1. Botox

Its generic name is called Botulinum toxin type A.

It is used to treat neck pains and abnormal head position which are associated with cervical dystonia. Also used to temporarily treat the appearance of moderate frown lines between the eyebrows and treatment of excessive underarm sweating.

1. Lexapro

Its generic name is Escitalopram.

It is mostly used for major depressive disorder (MDD) and generalized anxiety disorder (GAD).

1. Viberzi

Its generic name is called Eluxadoline

It is used for the treatment of irritable bowel syndrome with diarrhea.

1. Linzess

Its generic name is called Linaclotide

It is orally administered. It is used to treat irritable bowel syndrome with constipation and chronic constipation.

1. Dalvance

The generic name for this product is Dalbavancin.

Dalvance for injection is used to treat adult patients with bacterial skin infections.

1. Fetzima

The generic name for this product is called Levomilnacipran.

It is used in the treatment of major depressive disorder (MDD).

Product Recalls and Lawsuits

1. Taytulla 2018 Recall

In May 2018, Allergan pharmaceuticals made a recall for Taytulla, a birth control pill. The reason for the recall was due to the packaging error which could result in one getting pregnant.

The four placebo capsules were placed out of order and this meant that patients could receive four non hormonal capsules for the first four days of the therapy instead of the active pink capsules which should be taken as one daily and the followed by four maroon capsules up to the end of the month.

After this recall, some lawsuits were filed against the company for damages caused after using the drug with the wrong instructions. 

1. 2015 Refresh Lacri-Lube, Refresh P.M., FML, Blephamide Recall

Allergen Pharmaceuticals issued a voluntary recall in August 2015 of Refresh Lacri-Lube, Refresh P.M., FML, Blephamide due to potential contamination that could result to eye pain, swelling, irritation and ocular discomfort.

This recall was initiated by the company receiving complaints from customers of a small black particle contained in the drug which made the company to make this immediate and voluntary recall of the lots affected. This was in the interest of patient safety.

Litigation Settlements

1. $600 Million Botox Settlement

In September 2010, Allergan pharmaceuticals paid $600 million in settlement of charges that it promoted and sold illegally it Botox drug from the year 2005 for unapproved uses.

The government trough a civil case alleged that the company with vigor and without thought of the negative effects health wise illegally promoted this drug Botox for uses that were not deemed safe by FDA.

The company developed and put a vigorous marketing strategy program and even included paying kickbacks to doctors who prescribed this drug for the unapproved uses.

Allergan agreed to pay $375 million to the government for one criminal charge it pleaded guilty to and $225 million to be submitted to Medicaid, Medicare and other government programs for civil charges of causing false claims.

1. $313million  Celexa marketing claim Settlement 

In September 2010, Forest laboratories (now part of Allergan) the maker of Celexa paid $313 million to settle criminal and civil charges against it. It was alleged that the company drug for use in children for uses that were not yet approved by the FDA.

The company between the year 2000 and 2005 promoted and marketed the drug Celexa for uses which included cerebral palsy in children and headache instead the drug was approved for adult depression.

Sources:

https://www.allergan.com/about/company-profile

https://www.drugwatch.com/manufacturers/allergan/

https://www.nytimes.com/2010/09/16/health/16drug.html

https://www.crunchbase.com/organization/allergan/acquisitions/acquisitions_list#section-acquisitions

https://www.drugbank.ca/drugs/DB00083

 

Executive Summary

Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The Company with a global footprint in 49 countries, world-class manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the world’s emerging and developed markets.

Ranbaxy Laboratories Ltd. officially ceased to exist as a company in 2014, when Sun Pharma acquired it. 

History of Ranbaxy

Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. The name Ranbaxy is a portmanteau of the names of its first owners Ranbir and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranbir and Gurbax. After Bhai Mohan Singh’s son Parvinder Singh joined the company in 1967, the company saw an increase in scale.

In the late 1990s, Ranbaxy formed a US company, Ranbaxy Pharmaceuticals Inc., and to support its entry into the pharmaceutical market in United States.

In June 2008, Daiichi-Sankyo acquired a 34.8% stake in Ranbaxy from the family of CEO and Managing Director Malvinder Mohan Singh for USD 2.4 billion.

In November 2008, Daiichi-Sankyo completed the takeover of the company from the founding Singh family in a deal worth $4.6 billion by acquiring a 63.92% stake in Ranbaxy. Ranbaxy’s Malvinder Singh remained as CEO after the transaction. The addition of Ranbaxy Laboratories extended Daiichi-Sankyo’s operations, with the combined company worth about US$30 billion.

In 2009 it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the India operations of Ranbaxy Laboratories.

In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. In the 2012, 2013 and 2014 Brand Trust Reports, Ranbaxy was ranked 161st, 225th and 184th respectively among India’s most trusted brands.

On 7 April 2014 India based Sun Pharmaceutical and Japan based Daiichi Sankyo jointly announced the sale of the entire 63.4% share from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy, were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. After this acquisition, the partner Daiichi-Sankyo was to hold a stake of 9% in Sun Pharmaceutical.

Subsidiaries of Ranbaxy Labs:

As Sun Pharma has effectively acquired Ranbaxy Labs, its subsidiary companies are: 

• Aditya Acquisition Company Ltd
• Alkaloida Chemical Company Zrt
• Alkaloida Sweden AB
• AO Ranbaxy
• Basics GmbH
• Be-Tabs Investments proprietary Ltd
• Faststone Mercantile Company Private Limited
• Green Eco Development Centre Limited
• Laboratories Ranbaxy S.L
• Neetnav Real Estate Private Limited
• Office Pharmaceutique Industries et Hospitalier SARL
• OOO Sun Pharmaceutical Industries Ltd
• Open Joint Stock Company BIOSINTEZ
• Ranbaxy (Poland) Sp. Z o.O.
• Ranbaxy (S.A.) (Proprietary) Ltd.
• Ranbaxy (Thailand) Company Limited
• Ranbaxy (U.K.) Limited
• Ranbaxy Europe Limited
• Ranbaxy Farmaceutica Ltda.
• Ranbaxy Gmbh
• Ranbaxy Holdings (U.K.) Limited
• Ranbaxy Ireland Limited
• Ranbaxy Italia S.P.A
• Ranbaxy Nigeria Limited
• Ranbaxy Pharma Proprietary Ltd
• Ranbaxy Pharmaceuticals Canada Inc.
• Ranbaxy Pharmaceuticals Ukraine LLC
• Ranbaxy Pharmacie Generiques
• Ranbaxy(Malaysia) Sdn Bhd
• Realstone Multitrade Private Limited
• Rexcel Egypt Company LLC
• Skisen Labs Private Limited
• Softdeal Trading Company Private Limited
• SPIL DE Mexico S.A.de
• Sun Farmaceutica Do Brasil Ltda
• Sun Global Canada Pty Ltd
• Sun Global Development FZE
• Sun Laboratories FZE
• Sun Pharma ANZ Pty Ltd
• Sun Pharma De Mexico S.A.de
• Sun Pharma De Venezuela, C.A
• Sun Pharma East Africa Ltd
• Sun Pharma Global FZE
• Sun Pharma Healthcare FZE
• Sun Pharma Holdings USA Inc and entities
• Sun Pharma Holdings
• Sun Pharma Industries SAC
• Sun Pharma Japan Ltd
• Sun Pharma Laboratories Limited
• Sun Pharma (Netherlands) B.V.
• Sun Pharma Phillipines Inc.
• Sun Pharma SA Pty Ltd
• Sun Pharma Switzerland Ltd.
• Sun Pharmaceutical (Bangaldesh) Ltd
• Sun Pharmaceutical Industries (Australia) Pty Ltd
• Sun Pharmaceutical Industries (Europe) B.V.
• Sun Pharmaceutical Peru SAC
• Sun Pharmaceuticals France
• Sun Pharmaceuticals Germany GmbH
• Sun Pharmaceuticals Italia S.R.L.
• Sun Pharmaceuticals Korea Ltd
• Sun Pharmaceuticals Morocco Sarlau
• Sun Pharmaceuticals UK Limited
• Sunpharma Egypt LLC
• Taro Pharmaceutical Industries Ltd
• Terapia S.A.

Popular Pharmaceutical Products of Ranbaxy

The top products of Ranbaxy, with their therapeutic areas:

Abiraterone acetate*	Anti-Cancer
Acamprosate Calcium	CNS Stimulant
Acitretin	Dermatology
Adapalene	Retinoid agent
Adefovir Dipivoxil	AntiViral
Alendronate Sodium	Anti-Osteoporosis
Amifostine Trihydrate*	Radioprotective agent
Amisulpride	Anti-Psychotic
Amorolfine Hydrochloride	Dermatology
Amoxicillin Trihydrate	Antiinfective
Anastrozole	Anti-Cancer
Aripiprazole*	Anti-Psychotic
Asenapine Maleate*	Anti-Psychotic
Atazanavir Sulfate	AntiViral
Atomoxetine HCl*	ADHD Therapy
Atorvastatin Calcium Amorphous	Cardiovascular
Atorvastatin Calcium Crystalline	Cardiovascular
Atosiban Acetate	Oxytocin Antagonist
Azacitidine	Anti-Cancer
Benazepril Hydrochloride	Cardiovascular
Bendamustine*	Anti-Cancer
Bicalutamide	Anti-Androgen
Bivalirudin*	Anti-Coagulant
Bortezomib*	Multiple Myeloma
Bosentan Monohydrate	Cardiovascular
Budesonide	Anti-Inlammatory Steroid
Buprenorphine HCl	Analgesic
Bupropion HCl	Anti-Depressant
Calcipotriol Anhydrous	Psoriasis
Calcitonin (Salmon)	Anti-Osteoporosis
Candesartan cilexetil	Cardiovascular
Capecitabine	Anti-Cancer
Carboplatin	Anti-Cancer
Carvedilol	Anti-Hypertensive
Cefaclor	Antiinfective
Cefdinir	Antiinfective
Cefpodoxime proxetil	Antiinfective
Cefprozil	Antiinfective
Cefuroxime Axetil	Antibiotic
Celiprolol Hydrochloride	Cardiovascular
Cephalexin	Antiinfective
Cilastatin sodium sterile	Antiinfective
Cilazapril	Cardiovascular
Cinacalcet HCl*	Calcimimetic
Ciprofloxacin	Antiinfective
Ciprofloxacin Hydrochloride	Antiinfective
Cisplatin	Anti-Cancer
Citalopram Hydrobromide	CNS
Clarithromycin	Antiinfective
Clarithromycin Granules 27.5%	Antiinfective
Clarithromycin Granules 43.75%	Antiinfective
Clomipramine HCl	Anti-Depressant
Clonazepam	Anti-Epileptic
Clopidogrel Bisulphate	Anti-Thrombotic
Clorazepate Dipotassium	Anxiolytic
Colesevelam*	Bile acid Sequestrant
Dabigatran Etexilate Mesylate*	Anti-Coagulant
Decitabine	Myelodysplastic Syndrome
Deferasirox*	Iron Chelator
Desloratadine	Anti-Histaminic
Desmopressin Acetate	Vasopressin Analogue
Desvenlafaxine Fumarate	Anti-Depressant
Divalproex Sodium	Anti-Epileptic
Dobutamin HCl	Cardiovascular
Donepezil HCl	Anti-Alzheimer
Doripenem	Antiinfective
Dothiepin HCl	Anti-Depressant
Doxercalciferol*	Hyperparathyroidism
Doxycycline	Antiinfective
Doxycycline Hyclate	Antiinfective
Dronedarone	Anti-Arrhythmic
Drospirenone	Oral Contraceptive
Duloxetine	Anti-Depressant
Dydrogesterone	Hormone Replacement Therapy
Edaravone	Neuroprotective
Emtricitabine	AntiViral
Entecavir	AntiViral
Epinastine HCl	Anti-Histaminic
Epinephrine	Neurotransmitter
Epoprostenol Sodium	Prostaglandin
Eptiibatide*	Anti-Thrombotic
Escitalopram Oxalate	Anti-Depressant
Esomeprazole Magnesium (Amorphous)	Gastrointestinal
Esomeprazole Sodium	Proton pump inhibitor
Eszopiclone	Hypnotic
Exemestane	Anti-Cancer
Exenatide *	Anti-Diabetic
Febuxostat Form G	Antigout
Fesoterodine Fumarate*	Overactive bladder
Fexofenadine Hydrochloride	Antihistamine
Finasteride	Anti-Testosterone for BPH
Fingolimod Hydrochloride*	Immuno modulator
Flupirtine Maleate	Analgesic
Flurbiprofen	NSAID
Fluticasone Propionate	Anti-Allergic
Fluvastatin sodium	Cardiovascular
Fluvoxamine Maleate	Anti-Depressant
Fosamprenavir Calcium	AntiViral
Fosinopril sodium	Cardiovascular
Fosphenytoin Sodium	Anti-Epileptic
Fulvestrant	Anti-Cancer
Gabapentin	Anti-Epileptic
Galantamine Hydrobromide	CNS
Ganirelix Acetate*	GnRH Antagonist
Gemcitabine HCl	Anti-Cancer
Granisetron HCl	Anti-Emetic
Ibandronate Sodium	Anti-Osteoporosis
Imatinib Mesylate *	Anti-Cancer
Imipenem	Antiinfective
Irbesartan	Cardiovascular
Irinotecan	Anti-Cancer
Isotretinoin	Dermatology
Lacosamide*	Anti-Epileptic
Lamivudine	AntiViral
Lansoprazole	Gastrointestinal
Lenalidomide*	Anti-Cancer
Lercanidipine HCl	Anti-Hypertensive
Letrozole	Anti-Cancer
Leuprolide Acetate	Anti-Cancer
Levalbuterol HCl	Anti-Asthmatic
Levalbuterol Tartrate*	Anti- Asthmatic
Levetiracetam	Anti-Epileptic
Levocetirizine di HCl	Anti-Histaminic
Levofloxacin	Antiinfective
Levosulpiride	Anti-Psychotic
Linagliptin *	Anti-Diabetic
Liothyronine Sodium	Hormone Replacement Therapy
Lisinopril	Cardiovascular
Lopinavir	AntiViral
Loratadine	Antihistaminic
Lorazepam	CNS
Losartan Potassium	Anti-Hypertensive
Loteprednol Etabonate	Corticosteroid
Lubiprostone *	Laxative
Lurasidone HCl	Schizophrenia
Magnesium Valproate	Anti-Epileptic
Meloxicam	NSAID
Memantine HCl	Anti-Alzheimer
Meropenem	Antiinfective
Mesalazine/Mesalamine	Anti-Inlammatory
Metadoxine	Alcohol Abuse
Metformin HCl	Anti-Diabetic
Methyl Phenidate HCl	CNS Stimulant
Metoprolol Succinate	Anti-Hypertensive
Metoprolol Tartrate	Anti-Hypertensive
Midazolam	CNS
Mifepristone	Abortifacient
Milnacipran Hydrochloride	CNS
Mirtazapine Hemihydrate	Anti-Depressant
Montelukast Sodium	Anti-Asthmatic
Naloxone HCl	Opioid Antagonist
Naltrexone HCl	Opioid Antagonist
Naratriptan HCl	Anti-Migraine
Nevirapine	AntiViral
Octreotide Acetate	Anti-Cancer
Ofloxacin	Antiinfective
Olanzapine	Anti-Psychotic
Olopatadine HCl *	Anti-Allergic
Omeprazole Magnesium	CNS
Ondansetron Base	Anti-Emetic
Ondansetron HCl	Anti-Emetic
Orlistat	Antiobesity
Oxaliplatin	Anti-Cancer
Oxcarbazepine	Anti-Epileptic
Oxetacaine	Local-Anaesthetic
Paliperidone*	Anti-Psychotic
Pamidronate Disodium	Anti-Osteoporosis
Pantoprazole Sodium Sesquihydrate	Proton pump inhibitor
Paroxetine HCl	Anti-Depressant
Pemetrexed Disodium*	Anti-Cancer
Pentazocine	CNS
Pentoxifylline	Anti-Anginal
Phentermine HCl	Appetite Suppressant
Pioglitazone Hydrochloride	Antidiabetic
Pramipexole Di HCl	Anti-Parkinsons
Pramlintide Acetate	Anti-Diabetic
Prasugrel Hydrochloride*	Anti-Platelet
Pregabalin*	Anti-Epileptic
Quetiapine Fumarate	Anti-Psychotic
Quinapril Hydrochloride	Cardiovascular
Rabeprazole sodium	Gastrointestinal
Ramipril	Cardiovascular
Ranitidine Hydrochloride	Antihistaminic
Ranolazine	Anti-Angina
Rasagiline Mesylate*	Anti-Parkinsons
Repaglinide	Antidiabetic
Rifaximin	Anti-bacterial
Riluzole	Amyotrophic lateral sclerosis
Risedronate Sodium	Anti-Osteoporosis
Risperidone	Anti-Psychotic
Ritonavir	AntiViral
Rivastigmine Base	Anti-Parkinsons
Rivastigmine Tartrate	Anti-Parkinsons
Rizatriptan Benzoate	Anti-Histamine
Rosuvastatin Calcium*	Lipid lowering agent
Sertraline Hydrochloride Form I	CNS
Sevelamer Carbonate*	Hyperphosphatemia
Sevelamer HCl*	Hyperphosphatemia
Simvastatin	Cardiovascular
Sodium Valproate	Anti-Epileptic
Solifenacin Succinate	Antimuscarinic
Sumatriptan Succinate	Anti-Migraine
Tadalafil	Others
Tamsulosin Hydrochloride	Urology
Telmisartan	Cardiovascular
Temozolomide	Anti-Cancer
Tenofovir Disoproxil fumarate	AntiViral
Teriparatide	Anti-Osteoporosis
Terlipressin Acetate	Vasopressin Agent
Testosterone Cypionate	Hormone Replacement Therapy
Tiagabine HCl	Anti-Epileptic
Tizanidine HCl	Muscle Relaxant
Tolterodine tartrate	Antimuscarinic
Topiramate	Anti-Epileptic
Tramadol HCl	Opioid Analgesic
Valacyclovir Hydrochloride	AntiViral
Valgancyclovir Hydrochloride (Amorphous Grade)	AntiViral
Valgancyclovir Hydrochloride (Crystalline Grade)	AntiViral
Valproic Acid	Anti-Epileptic
Valsartan	Cardiovascular
Venlafaxine Hydrochloride	CNS
Voglibose	Antidiabetic
Voriconazole	Antifungal
Zoledronic Acid	Anti-Osteoporosis
Zolmitriptan	Anti-Migraine
Zolpidem Tartrate	CNS
Zonisamide	Anti-Epileptic

Product Recalls and Lawsuits

1. In March 2015, Ranbaxy Laboratories Ltd was sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market. The suit alleged that Ranbaxy filed “grossly inadequate” applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity. 
2. In May 2013, Ranbaxy pleaded guilty to federal drug safety violations and paid $500 million in fines to resolve claims that it sold subpar drugs and made false statements to the Food and Drug Administration about its manufacturing practices at two factories in India.
3. In 2012, Ranbaxy issued a voluntary retail-level recall for Atorvastatin calcium tablets (Lipitor) because it contained glass particles. Class action lawsuits were filed in New Jersey, United States. 
4. In 2014, Ranbaxy issued a recall for Atorvastatin calcium after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the U.S. Food and Drug Administration (FDA) said on its website.
5. In 2015, Ranbaxy Laboratories Ltd. recalled nearly 30,000 packages of an allergy relief medication – loratadine and pseudoephedrine sulphate packages – that made its way to the United States in February. The U.S. Food and Drug Administration noted that the product was recalled as the result of defective packaging.
6. In 2015, Ranbaxy’s parent company Sun Pharma voluntarily recalled 200 vials of its cancer drug, gemcitabine, in the United States. This was because of lack of assurance of sterility of the vials. 

Litigation Settlements

1. In 2010, Ranbaxy Laboratories Limited and Ranbaxy USA agreed to settle a whistleblower lawsuit and will pay a record $500 million in fines and penalties. This is the largest financial penalty levied against a generic drug company for violations of the Federal Food, Drug and Cosmetic Act. The violations revolve around safety violations that occurred at Ranbaxy USA, a subsidiary of the generic pharmaceutical manufacturer Ranbaxy Laboratories. They generic drug manufacturer is accused of allowing tainted drugs from two manufacturing facilities in India to be distributed within the United States market. As part of the settlement, Ranbaxy agreed to pay to a fine and forfeiture of $150 million, as well as an additional $350 million penalty to settle the civil claims that they submitted false statements to Medicaid, Medicare and other government healthcare programs. Approximately $49 million of the penalty will go to the whistleblower.
2. In 2014, Ranbaxy Laboratories paid $39.75 million in tranches to the state of Texas in the U.S. to settle the litigation concerning its participation in the Texas Medicaid Program.
3. In 2013, Ranbaxy paid around $420,000 to the U.S. state of Idaho as part of a $500-million settlement that the drug firm had signed with U.S. authorities.
4. In 2017, Ranbaxy Laboratories agreed to settle lawsuits accusing it of accepting payments from pharmaceutical company Cephalon Inc to delay the release of a generic version of the latter’s wakefulness drug Provigil.
5. In 2008, Ranbaxy settled with pharma giant AstraZeneca in an agreement that will keep Ranbaxy’s generic copies of the blockbuster heartburn drug Nexium off the U.S. market until 2014.
6. In 2009, Ranbaxy Laboratories was been slapped with tough penalties by the US Food and Drug Administration (FDA) after it was repeatedly caught falsifying data from one of its four Indian manufacturing plants.

Sources:

https://www.cnbc.com/id/100261384

https://www.abrahamwatkins.com/blog/2012/11/ranbaxy-pharmaceuticals-drug-recall.shtml

https://www.nature.com/news/2009/090302/full/news.2009.130.html

https://www.wsj.com/articles/SB120824391214015579

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=878399

Executive Summary

Watson pharmaceutical is a leading pharmaceutical company globally which is mainly engaged in developing, manufacturing, marketing and distribution of generic products. The company is located and headquartered in Corona, California, United States.

The company’s generic business is focused on the maintaining of the leading position in the US market where the company is currently ranked the third in annual prescriptions dispensation.

The company’s product portfolio is quite wide and ranges from hypertension, antibiotics, pain management, smoking and many other more.

The company’s global supply chain is ensuring that everyone is getting this great service from Watson pharmaceuticals because it is the duty of the company to offer value to the customers and patients for betterment of their lives.

The company has employed more than 7500 employees and they work together day and night to see the company core goals.

History of Watson Pharmaceuticals

Watson pharmaceutical was launched in the early 1980s when there was a great blooming market for the generic drugs. Generic drugs are mainly drugs that are usually off brand drugs but which are chemically the same as their main brand cousins.

Watson pharmaceutical was formed in 1985 and grew very significantly and in the 1990s, the company made key acquisitions and this expanded its base widely in the US market.

This company now operates as the fifth pharmaceutical company in the United States and it grows day in and out. It is much focused in ensuring that the market which is the consumers is reached with their unmet needs and a solution is offered to their medical and health needs.

Subsidiaries of Watson Pharmaceuticals

1. Andrx Corporation

In April 2006, Watson pharmaceuticals acquired Andrx Corporation at a cost of $1.9 billion cash. The company was established in 1992 and is based in Davie, Florida United States.

This company mainly develops, manufacture and engages in the distribution and commercialization of the generic versions of controlled release pharmaceuticals and oral contraceptives and also in the release of immediate generic products. 

After this acquisition, the company was full acquired by Watson pharmaceuticals and became part of this family.

1. Eden Biopharma Group

Watson pharmaceuticals acquired Eden biopharma group in January 2010 at a cost of $15 million in cash. This company was established in the year 2000 and it is located in Liverpool United Kingdom.

Eden biopharma group is a biopharmaceutical development consultancy which is focused in the provision of biopharmaceutical drug development and manufacturing services.

The company’s sole engagement is the product and process development, technical and regulatory support, strategic planning development, management outsourcing, technology transfers and in the coordination of clinical trial supplies

It always serves main pharmaceutical and biotechnology companies which are located in the United Kingdom, Australia, and Asia and in the entire Europe.

1. Uteron Pharma

This is company which is committed to enabling research that is driven by the women’s needs. It develops women’s health products. 

The company offers Loveset which is a hormonal intra uterine device which in a consistent form releases very small quantities of levonorgestrel in the uterine cavity.

It also provides Diafert which is a non invasive adjunctive in vitro fertilization in the improvement of embryo selection during the assisted reproductive procedures.

The company was established in 2002 and is based in Grace-Hologne, Belgium.

Watson pharmaceuticals acquired Uteron pharma in January 2013 at a cost of $355 million which was $150 million in upfront cash and $155 million in future milestones.

1. Schein Pharmaceuticals

Schein pharmaceutical is a pharmaceutical company that was established in 1993. The company develops, manufactures and does the marketing of generic products in the healthcare industry.

The company is located in Melville, New York, United States.

In May 2000, Watson pharmaceuticals acquired the Schein pharmaceutical at a cost of $674 million in cash basis to take it over which became a whole subsidiary of Watson pharmaceuticals.

Popular Products of Watson Pharmaceuticals

1. Lipitor

Its generic name is called Atorvastatin.

It is used alongside with the diet to lower bad cholesterol and fats and raise good cholesterol in the blood. It belongs to the group of drugs which are called Statins. It works by reducing the amount of much cholesterol which is produced by the liver.

This lowering of bad cholesterol and increasing good cholesterol reduces much the risk of getting heart diseases and in the prevention of heart attacks and stroke.

Together with eating good diet, there are other lifestyle changes that may help too this drug in working better and achieving the required results such like; losing weight if overweight, stopping to smoke and doing a lot of exercises.

In using this drug Atorvastatin, follow the doctors’ prescriptions seriously and take this medicine directly by mouth with or without food.

Its side effects may include mild memory problems and sort of confusion with people taking this medicine

1. Fentanyl

Its generic name is also called Fentinil.

This is the drug which is used as pain medication and under the opioid drugs. Opioid medications are the drugs that treat very severe pains where other medications have totally failed to work. 

It is a potent synthetic opioid excellent for controlling serious pain but which has also very huge abuse potential. This drug is also sometimes used as a recreational drug often mixed with heroin or cocaine.

This medication has short term effects which includes euphoria, relaxation and reduced feeling of pain. The side effects include vomiting, nausea, constipation, confusion, some weakness and sweating.

1. Propafenone HCL

Its generic name is called Propafenone.

It is normally used to treat very serious and irregular human heartbeats. It is used to restore normal heart rhythm and also to maintain regular and steady heartbeat.

It normally works by blocking some activities of certain electrical signals in the heart which are likely to cause irregular heartbeats. It is highly recommended that you treat irregular heartbeats as if left unattended can cause blood clotting hence leading to the heart attacks or stroke.

This medication is usually taken by mouth and with or without food is okay. Always follow the doctor’s instructions as the dosage usually depends on the medical condition at hand hence it is only the doctor who can know how to prescribe.

The side effects of this drug mostly are dizziness, nausea, constipation, vomiting and anxiety.

Product Recalls and Lawsuits

1. 2008 Fentanyl Drug Recall

In August 2008, Watson pharmaceuticals made a recall of Fentanyl patches. This recall was for one lot of Fentanyl transdermal system patches because there was a detection of Fentanyl patches gel leaking.

The exposure to the leaked Fentanyl gel could lead to possible overdose and respiratory depression. The Fentanyl transdermal system patches are mainly used in the management of persistent and moderate to severe chronic pain which require all time round the clock opioid administration. 

1. 2009 Propafenone Recall

Watson pharmaceuticals made a voluntary recall of propafenone HCL tablets in March 2009. One lot of Propafenone HCL 225mgtablets which is in bottles and is mostly sold in the US is being recalled up to the level of the consumer.

The recalled tablets were manufactured by Watson pharmaceuticals and were being recalled because of oversized tablets. This is because some of them contained some higher ingredients than it is specified and this led to the oversize. 

The affected lots were distributed to the consumers between the dates of October 15, 2008 and November 26, 2008. No other lots were affected apart from these ones.

Propafenone is a product which is mainly used in the treatment of irregular heartbeats. It has a narrow therapeutic index and this affects patients who are very sensitive to very small variations and due to this, these tablets could have caused dose variations which in return will result in serious side effects. This is the reason why Watson recalled this up to the consumer level in order to minimize any risk that may be brought about.

Litigation Settlements

1. $18 Million Elan’s Naproxen Sodium Litigation

In March 2006, Watson pharmaceuticals reached an agreement with Elan Corporation over patent litigation which was related to Watson’s Naproxen sodium commonly called Naprelan tablets.

Under the terms of this agreement, Watson paid Elan $18 million in full settlement of all disputes that emerged from Watson’s development, manufacture, and distribution of the drug Naprelan. 

The case was fully settled from that time and the two companies continued with their business as usual.

1. $33 million Mississippi Litigation Settlement.

On January 2018, Watson pharmaceuticals agreed to pay $33 million to Mississippi over the alleged lawsuit that the company inflated prices of its drugs which were paid by the Mississippi federal state for the state Medicaid health insurance program.

It was alleged that the company defrauded the taxpayers of Mississippi by an estimated amount of over $7 million. This inflated prices varied from drug to drug and to some drugs the inflation went up to 1000%. Due to this the court awarded the federal state this amount of settlement. Under this settlement of $33 million, $8 million were compensatory damages to the Medicaid of Mississippi unit, $5 million as civil penalties and $20 million as punitive damages.

Sources:

https://www.crunchbase.com/organization/watson-pharmaceuticals#section-overview

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=10965584

https://www.policymed.com/2018/02/watson-pharmaceuticals-now-part-of-teva-to-pay-33-million-to-mississippi.html

https://www.webmd.com/drugs/2/drug-841/atorvastatin-oral/details